Clinical bottom line
Allergic reactions to novel gene therapy agents represent an emerging challenge in allergy practice as these therapies become more widespread. Current evidence highlights the complexity of immune responses to gene vectors and transgene products, which can trigger IgE-mediated and non-IgE hypersensitivity reactions. Diagnosis relies on a combination of detailed clinical history, skin testing, and emerging in vitro assays, though standardized protocols remain under development. Management strategies emphasize prompt recognition, avoidance of culprit agents, and tailored desensitization protocols when re-exposure is necessary. Given the novelty of gene therapies, clinicians should maintain vigilance for atypical presentations and collaborate closely with immunologists and gene therapy specialists. This digest summarizes current understanding and practical considerations for allergy clinicians encountering suspected allergic reactions to gene therapy.
What the evidence shows
Gene therapy introduces genetic material into patients to treat or prevent disease, often using viral vectors such as adeno-associated viruses (AAV) or lentiviruses. These vectors and their transgene products can elicit immune responses ranging from mild hypersensitivity to severe anaphylaxis (Sitek et al., 2023). The pathophysiology involves both innate and adaptive immunity, with IgE-mediated mechanisms implicated in immediate-type hypersensitivity, while delayed-type reactions may involve T-cell mediated pathways (Allergy in Practice, 2006).
Diagnosis of allergic reactions to gene therapy agents is challenging due to limited validated testing methods. Skin prick and intradermal testing with vector components or transgene proteins can be informative but lack standardized reagents and protocols (Hamilton et al., 2010). In vitro assays, including basophil activation tests and specific IgE measurement, are under investigation but not yet widely available or validated for gene therapy antigens (The Journal of Allergy and Clinical Immunology: In Practice, 2020). Clinical history remains paramount, focusing on timing, symptomatology, and prior exposures.
Management mirrors principles established for biologic therapies and drug hypersensitivity. Immediate reactions require prompt treatment with epinephrine, antihistamines, and corticosteroids as indicated (Sitek et al., 2023). For patients requiring ongoing gene therapy, graded desensitization protocols adapted from biologic allergy management may be considered, though evidence is limited (Anderson et al., 2010). Pre-medication strategies and slow infusion rates may mitigate risk but require further study.
Caveats and uncertainty
The field of allergic reactions to gene therapy is nascent, with most data derived from case reports, small series, or extrapolation from biologic drug hypersensitivity literature (Sitek et al., 2023). There is a lack of standardized diagnostic reagents and consensus guidelines specific to gene therapy agents. The heterogeneity of gene therapy platforms and patient immune backgrounds complicates risk stratification and generalization of findings.
Furthermore, distinguishing true IgE-mediated allergy from non-allergic infusion reactions or immune complex-mediated phenomena can be difficult and may require multidisciplinary evaluation. Long-term immunogenicity and the impact of repeated dosing on allergic sensitization remain poorly understood. Clinicians should interpret diagnostic tests cautiously and consider consultation with allergy specialists experienced in drug and biologic hypersensitivity.
How this may change practice
As gene therapies expand in clinical use, allergy clinicians will increasingly encounter patients with suspected allergic reactions to these agents. Awareness of the potential for both immediate and delayed hypersensitivity is essential for timely diagnosis and management. Incorporating detailed exposure histories and considering referral for specialized testing will improve diagnostic accuracy.
Clinicians should anticipate the need for individualized management plans, including possible desensitization or alternative therapeutic strategies, in collaboration with gene therapy teams. Development and adoption of standardized testing protocols and reporting of allergic reactions will enhance understanding and guide evidence-based practice. Ultimately, integrating allergy expertise into gene therapy programs may improve patient safety and treatment outcomes.